Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2025-08-20 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 87% confidence The document is a ‘Next Day Disclosure Return’ under Hong Kong Stock Exchange rules (Main Board Rule 13.25A/GEM Rule 17.27A), detailing changes in issued shares due to conversion of bonds into new ordinary shares. It reports the number of shares issued and closing balances, with no repurchases. This is a formal share capital change announcement, matching the ‘Share Issue/Capital Change’ category (Code: SHA).
2025-08-20 English
OVERSEAS REGULATORY ANNOUNCEMENT
Share Issue/Capital Change Classification · 90% confidence The document is an announcement by Luye Pharma Group Ltd. under Rule 13.10B of the HK Listing Rules describing the conversion of US$25 million of its 5.85% convertible bonds into 52,919,389 new shares. It details the allotment of conversion shares, adjustments to the total share count and outstanding bond principal, and constitutes a change in the company’s capital structure through a new share issue. This aligns with the “Share Issue/Capital Change” category (SHA).
2025-08-20 English
NOTICE OF BOARD MEETING
Report Publication Announcement Classification · 91% confidence The document is a brief announcement (“NOTICE OF BOARD MEETING”) stating the date when the board will meet to approve and publish the interim results for the six months ended 30 June 2025. It does not contain any financial figures or the interim report itself, but simply notifies investors of the timing of the board meeting and forthcoming report publication. This fits the “Report Publication Announcement” category rather than an actual Interim Report (IR) or any other substantive filing.
2025-08-18 English
VOLUNTARY ANNOUNCEMENT PATIENT ENROLLMENT COMPLETED FOR THE PHASE III CLINICAL STUDY OF RUOXINLIN IN CHINA FOR TREATING GENERALIZED ANXIETY DISORDER
Regulatory Filings Classification · 80% confidence The document is a voluntary announcement on the Hong Kong Exchange regarding completion of patient enrollment for a Phase III clinical trial. It contains no financial results, management discussion, dividend information, share issuance, legal proceedings, or other specified reporting categories. It is an event update required by the exchange but does not fit any specialized filing type (e.g., earnings release, interim report, M&A, board changes). Therefore, it falls into the fallback category of a general regulatory announcement.
2025-08-18 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 AUGUST 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement by Majestic Dragon Aerotech Holdings Limited disclosing the poll results of its Annual General Meeting held on 15 August 2025. It lists vote counts for ordinary resolutions proposed at the AGM. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements” (Code: DVA).
2025-08-15 English
OVERSEAS REGULATORY ANNOUNCEMENT
Share Issue/Capital Change Classification · 95% confidence The document is an announcement under Hong Kong Listing Rule 13.10B reporting the conversion of US$25,000,000 of 5.85% convertible bonds into 52,919,389 new shares, with details of share counts before and after conversion. This is a corporate action resulting in an issuance of new shares (capital change). It does not present full financial results or request votes, but specifically describes a share issuance via bond conversion. Therefore it is a Share Issue/Capital Change announcement (SHA).
2025-08-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.